Previous 10 | Next 10 |
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors. Dr. Martinborough has over t...
Roubaix Capital, LLC provides investment advisory services. The Company offers investment and portfolio management services for pooled investment vehicles. Roubaix Capital serves customers in the U.S. During the fourth quarter of 2020, the Roubaix Fund Composite gained 26.63% on a net...
REDWOOD CITY, Calif. and HOFFMANN ESTATES, Ill., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Tate & Lyle (LSE: TATE.L), a leading global provider of food ingredients and solutions, h...
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that John Nicols, the Company’s President and Chief Executive officer, will participate in a fireside chat presentation at the H.C. Wainwright B...
The seasonally-strongest baskets include gold and technology. The top stocks in each major sector right now. The best sectors include consumer goods, industrial goods, and financials. For further details see: The Top Stocks To Buy In The New Year
What the January effect means for small cap stocks. The strongest small-cap sectors and industries. The top small-cap stocks to buy now. For further details see: The Best Small-Cap Stocks To Buy Because Of The January Effect
Codexis (CDXS) has priced its public offering of 4,285,715 common shares at $17.50/share, for expected net proceeds of ~$70.2M.Underwriters' over-allotment is an additional 642,857 shares. Net proceeds will be used to fund R&D activities, for product development and for general corporate ...
REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $17.50 per share. Net proceeds to ...
Codexis (CDXS) announces an underwritten public offering of shares of its common stock.Underwriters' option to purchase up to an additional 15% shares.Size and terms yet to be finalisedNet proceeds to be deployed for accelerating development of its performance enzyme products and novel b...
REDWOOD CITY, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Co...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...